Background: Vascular-access patency is critical for effective and uninterrupted haemodialysis. Limited literature exists evaluating if a surgical or repeated radiological approach is superior for reocclusion following failure of radiological recanalization. Few consistent early predictors of failure have been identified after radiological intervention for thrombosed vascular access. Methods: 138 patients with thrombosed arteriovenous fistulas or prosthetic grafts treated by radiological intervention, over 10 years, were retrospectively investigated. Reocclusion was treated by either repeated thrombolysis or surgery. Radiological patency rates, after first and second episodes of access thrombosis at 12 months after intervention were analysed. Surgical and radiological patency rates for second access thrombosis were compared. The Cox and logistic regression models were used to identify potential factors associated with reocclusion. Results: In patients who experienced reocclusion within 1 month after radiological intervention, the 3-month repeated radiological patency rate (n = 13) was 38.5%, compared to a 60% surgical patency rate (n = 10), but this did not reach statistical significance. Radiological patency rates after first access thrombosis at 3 and 12 months were 56.6 and 39.5%, respectively. In contrast, radiological patency rates after a second access thrombosis were 51.1 and 24.4%, respectively; a statistical difference in success was not achieved. Native arteriovenous fistulas were 3.23 times as likely to remain patent over 12 months following a first radiological intervention (p < 0.02) and less likely to experience a second reocclusion event (p < 0.01). Anticoagulation was associated with a lower risk of second reocclusion, whilst a history of venous thrombosis was associated with a greater risk (p < 0.02). Conclusion: Surgery achieves superior patency rates compared to repeated radiological interventions and should be considered if reocclusion occurs within a month following radiological thrombolysis.

Keywords:
Fistula, Haemodialysis, Vascular-access patency, Radiology, Surgery
1.
Danovitch GM, Cohen DJ, Weir MR, et al: Current status of kidney and pancreas transplantation in the United States, 1994–2003. Am J Transplant 2005;5:904–915.
2.
McDonald S: ANZDATA Registry Report 2005 (unpublished data). Adelaide, Australia and New Zealand Dialysis and Transplant Registry, 2006.
3.
Chadban S, McDonald S, Livingston B, Excell L: Transplant waiting list; in McDonald S, Chang S, Excell L (eds): ANZDATA Registry Report 2005. Adelaide, Australia and New Zealand Dialysis and Transplant Registry, 2006, pp 103–105.
4.
Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF, Berlin JA: Haemodialysis vascular access morbidity in the United States. Kidney Int 1993;43:1091–1096.
5.
Hakim R, Himmelfarb J: Haemodialysis access failure: a call to action. Kidney Int 1998;54:1029––1040.
6.
Turmel-Rodrigues L, Pengloan J, Rodrigue H, et al: Treatment of failed native arteriovenous fistulae for haemodialysis by interventional radiology. Kidney Int 2000;57:1124–1140.
7.
Schon D, Mishler R: Salvage of occluded autologous arteriovenous fistulae. Am J Kidney Dis 2000;36:804–810.
8.
Haage P, Vorwerk D, Wildberger JE, Piroth W, Schurmann K, Gunther RW: Percutaneous treatment of thrombosed primary arteriovenous haemodialysis access fistulae. Kidney Int 2000;57:1169–1175.
9.
Liang HL, Pan HB, Chung HM, et al: Restoration of thrombosed Brescia-Cimino dialysis fistulas by using percutaneous transluminal angioplasty. Radiology 2002;223:339– 344.
10.
Shatsky JB, Berns JS, Clark TW et al: Single-centre experience with the Arrow-Trerotola Percutaneous Thrombectomy Device in the management of thrombosed native dialysis fistulas. J Vasc Interv Radiol 2005;16:1605–1611.
11.
Rajan DK, Clark TW, Simons ME, Kachura JR, Sniderman K: Procedural success and patency after percutaneous treatment of thrombosed autogenous arteriovenous dialysis fistulas. J Vasc Interv Radiol 2002;16:1605–1611.
12.
Hodges T, Fillinger M, Zwolak R, Walsh D, Bech F, Cronenwett J: Longitudinal comparison of dialysis access methods: risk factors for failure. J Vasc Surg 1997;26:1009–1019.
13.
Yasuhara H, Shigematsu H, Muto T: Results of arteriovenous fistula revision in the forearm. Am J Surg 1997;174:83–86.
14.
Young EW, Dykstra DM, Goodkin DA, Mapes DL, Wolfe RA, Held PJ: Haemodialysis vascular access preferences and outcomes in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 2002;61:2266–2671.
15.
Turmel-Rodrigues L, Pengloan J, Baudin S, et al: Treatment of stenosis and thrombosis in haemodialysis fistulas and grafts by interventional radiology. Nephrol Dial Transplant 2000;15:2029–2036.
16.
Clark TW, Hirsch DA, Jindal KJ, Veugelers PJ, Le Blanc J: Outcome and prognostic factors of restenosis after percutaneous treatment of native haemodialysis fistulas. J Vasc Interv Radiol 2002;13:51–59.
17.
Rajan DK, Bunston S, Misra S, Pinto R, Lok CE: Dysfunctional autogenous haemodialysis fistulas: outcomes after angioplasty – are there clinical predictors of patency? Radiology 2004;232:508–515.
18.
Crowther MA, Clase CM, Margetts PJ, et al: Low-intensity warfarin is ineffective for the prevention of PTFE graft failure for patients on haemodialysis: a randomized controlled trial. J Am Soc Nephrol 2002;13:2331–2337.
19.
Kaufman JS, O’Connor TZ, Zhang JH, et al: Veterans Affairs Cooperative Study Group on Haemodialysis Access Graft Thrombosis: randomized controlled trial of clopidogrel plus aspirin to prevent haemodialysis access graft thrombosis. J Am Soc Nephrol 2003;14:2313–2321.
20.
Le Sar CJ, Merrick HW, Smith MR: Thrombotic complications resulting from hypercoagulable states in chronic haemodialysis vascular access. J Am Coll Surg 1999;189:73–79.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.